AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

11,780.00p
   
  • Change Today:
    -118.00p
  • 52 Week High: 13,276.00
  • 52 Week Low: 9,501.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.29m
  • Volume: 3,460,879
  • Market Cap: £182,624m
  • RiskGrade: 123

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart (20-09-2024)

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

AstraZeneca Financials

Latest F'cast
Div Yield 1.8% 0.0%
Div Cover 1.3 2.6
Op Mrgn 17.9% 29.2%
ROCE 62.6%  
Latest F'cast
P/E 40.8 19.1
PEG 0.5 0.2
Pr/Revenue 5.3 3.5
Pr/Book 6.2  
Latest F'cast
Revenue 3.3% -14.6%
PBT 175.8% 65.8%
EPS 81.1% 110.9%
DPS n/a -38.5%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 24,384.00 1,548.00 103.00¢ 98.4 n/a -39% 280.00¢ 2.8%
31-Dec-20 26,617.00 3,916.00 244.00¢ 40.0 0.3 +137% 280.00¢ 2.9%
31-Dec-21 37,417.00 (265.00) 8.00¢ 1,445.1 n/a -97% 287.00¢ 2.5%
31-Dec-22 44,351.00 2,501.00 212.00¢ 70.5 0.0 +2,550% 290.00¢ 1.9%
31-Dec-23 45,811.00 6,899.00 384.00¢ 36.8 0.5 +81% 290.00¢ 2.1%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-24 52,138.78 15,241.14 616.74p 19.1 0.2 +111% 237.66p 0.0%
31-Dec-25 56,105.38 17,508.25 712.20p 16.5 1.1 +16% 249.41p 0.0%
31-Dec-26 59,562.86 19,889.21 786.36p 15.0 1.4 +10% 261.90p 0.0%

Copyright © 2024 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

FluMist approved for self-administration in US 20-Sep-2024 18:00 RNS
Fasenra EGPA US FDA approval 18-Sep-2024 07:00 RNS
Director/PDMR Shareholding 13-Sep-2024 15:15 RNS

AstraZeneca ShareCast News

AstraZeneca's inflammatory disease drug Fasenra ... 18-Sep-2024 ShareCast
London close: Stocks finish firmer in subdued tr... 13-Sep-2024 ShareCast
London close: Stocks mixed on latest UK jobs data 10-Sep-2024 ShareCast

AstraZeneca Top Newspaper Links

AstraZeneca shares slip after cancer drug trial ... 10-Sep-2024 Times
Fighting Frenchman shows us how as he ensures As... 30-Dec-2014 Daily Mail
Exclusive: UK firms vie for share of £170bn in A... 08-Dec-2014 The Independent

Latest AstraZeneca Director Deals

Traded Action Notifier PriceAmountValue
13-Sep-24 Buy Michel Demare 117.93p 2,000 £2,358.55

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 11,780.00p
Change Today -118.00p
% Change -0.99 %
52 Week High 13,276.00
52 Week Low 9,501.00
Volume 3,460,879
Shares Issued 1,550.29m
Market Cap £182,624m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.44% below the market average92.44% below the market average92.44% below the market average92.44% below the market average92.44% below the market average
95.92% below the sector average95.92% below the sector average95.92% below the sector average95.92% below the sector average95.92% below the sector average
Price Trend
56.23% above the market average56.23% above the market average56.23% above the market average56.23% above the market average56.23% above the market average
79.59% above the sector average79.59% above the sector average79.59% above the sector average79.59% above the sector average79.59% above the sector average
Income
89.61% below the market average89.61% below the market average89.61% below the market average89.61% below the market average89.61% below the market average
71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average
Growth
88.03% above the market average88.03% above the market average88.03% above the market average88.03% above the market average88.03% above the market average
93.94% above the sector average93.94% above the sector average93.94% above the sector average93.94% above the sector average93.94% above the sector average

What The Brokers Say

Strong Buy 9
Buy 15
Neutral 5
Sell 0
Strong Sell 1
Total 30
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 08-Aug-24 22-Feb-24
Paid 09-Sep-24 25-Mar-24
Amount 100.00¢ 197.00¢

Trades for 20-Sep-2024

Time Volume / Share Price
16:47 217 @ 11,780.00p
16:45 217 @ 11,780.00p
16:42 248 @ 11,780.00p
16:42 1 @ 11,780.00p
16:42 1,240 @ 11,780.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page